An Unwavering Commitment to Discovery

For 140 years, Lilly has sought new and better ways to help people live longer, healthier, more active lives. While the frontiers of science, our world’s communities and the global economy have all changed over the decades, our commitment to this mission has never wavered.

This week, we announced an upcoming transition in our leadership: current CEO John Lechleiter will retire at the end of this year, and beginning on January 1, 2017, Dave Ricks will become Lilly’s president and CEO. After working at Lilly for two decades, Dave understands our company’s mission and values, and is poised to successfully meet the challenges and opportunities the future holds. Through his close relationship with Europe and his Board level engagement at our European trade association EFPIA, he is familiar with the current and future healthcare challenges in Europe as well as the significant opportunity for innovation and economic growth.

Lilly is in the midst of one of the most productive periods for new medicines in our company’s long history, with the potential to launch 20 new medicines by 2024—medicines that we believe can truly improve the lives of European citizens. And, we’re continuing to make large investments in the research and discovery and manufacturing in Europe, making full use of the skills base, to create both new treatments and high quality jobs.

We strive every day to live up to our promise to unite caring with discovery to make life better for people around the world. With Dave as our CEO, we’ll continue to build and manage our pipeline, push the boundaries of scientific discovery and live out our values of integrity, excellence, and respect for people. Together, we’ll make a meaningful impact to health care and to our communities.